[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III

Program: Oral and Poster Abstracts
Type: Poster
Monday, December 12, 2011: 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)
DNMT3B Expression Delays Leukemogenesis 

Petra Tschanter, MD1*, Isabell Schulze1*, Nicole Bäumer1*, Beate Surmann1*, Konstantin Agelopoulos1*, Utz Krug, MD1, Wolfgang E. Berdel, MD1*, Heinz Linhart2* and Carsten Müller-Tidow, MD1,3*

1Department of Medicine A - Hematology, Oncology and Pneumology, University of Muenster, Muenster, Germany
2Department of Gastroenterology and Hepatology, University Hospital Freiburg, Freiburg, Germany
3Interdisciplinary Center for Clinical Research (IZKF), University of Muenster, Muenster, Germany

Microarray Gene Expression Signature Indicates ARSD As a New Marker Associated with Igvh Mutational Status, ZAP-70 and Disease Progression in CLL

Alessandra Trojani1*, Barbara Di Camillo2*, Alessandra Tedeschi3*, Lodola Milena3*, Simona Montesano4*, Francesca Ricci3*, Eleonora Vismara3*, Antonino Greco3*, Silvio Veronese5*, Anna Colosimo5*, Barbara Scarpati5*, Aldo Orlacchio4*, Sabata Martino4*, Chiara Colombo3*, Maria Angela Mura5*, Michele Nichelatti3*, Marco Montillo3 and Enrica Morra3

1Niguarda Hospital, Division of Hematology, Milano, Italy
2University of Padova, Department of Information Engineering
3Niguarda Hospital, Division of Hematology
4University of Perugia, Department of Experimental Medicine
5Niguarda Hospital

Gene Expression Profiling of Age-Related Epstein-Barr Virus (EBV)-Associated B-Cell Lymphoproliferative Disorder Uncovers Alterations in Immune and Inflammatory Genes: Possible Implications for Pathogenesis

Harumi Kato, MD1,2,3*, Kazuhito Yamamoto, MD, PhD2, Kennosuke Karube, MD, PhD1*, Miyuki Katayama, MD, PhD1*, Shinobu Tsuzuki, MD, PhD1, Yasushi Yatabe, MD, PhD4*, Jun Takizawa, MD, PhD5*, Koichi Ohshima, MD, PhD6*, Shigeo Nakamura, MD, PhD4,7, Yasuo Morishima, MD, PhD2 and Masao Seto, MD, PhD1,3

1Div. of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan
2Dept. of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
3Dept. of Cancer Genetics, Nagoya University Graduate School of Medicine, Nagoya, Japan
4Dept. of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
5Div. of Hematology, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan
6Dept. of Pathology, Kurume University, Kurume, Japan
7Dept. of Pathology and Clinical Laboratories, Nagoya University graduate school of medicine, Nagoya, Japan

Central Nervous System Involvement in a Xenograft Model of Pre-B Acute Lymphoblastic Leukaemia Is Associated with Dysfunctional CXCR4 Expression and Upregulation of the Neurotropic Chemokine Receptors CCR6 and CX3CR1

Christina Halsey, MD, PhD1, Mark TS Williams, PhD1*, Yasar Yousafzai, MD1*, Klaus Rehe, MD2*, Olaf Heidenreich, PhD2*, Josef Vormoor, MD2, Brenda Gibson3 and Gerard Graham, PhD1*

1Research Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
3Dept of Paediatric Haematology, Royal Hospital for Sick Children, Glasgow, United Kingdom

Allelic Methylation Levels of the Non-Coding RNA Gene VTRNA2-1 Located on Chromosome 5q31.1 Predict Outcome in AML

Marianne B. Treppendahl, MD1*, Xiangning Qiu, MD2*, Alexandra Søgaard, MSc1*, Cecilie Nandrup-Bus, MSc1*, Christoffer Hother, MD1*, Mette Klarskov Andersen, MD3*, Lars Kjeldsen, MD, PhD1, Lars Möllgård, MD4*, Eva Hellstrom-Lindberg, MD, PhD4, Johan Jendholm, MSc5*, Bo T. Porse, PhD5*, Peter A. Jones, PhD, DSc2*, Gangning Liang, PhD2* and Kirsten Grønbæk, MD, DMSc1*

1Department of Hematology, Rigshospitalet, Copenhagen, Denmark
2Department of Biochemistry and Molecular Biology, USC, Los Angeles, CA
3Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark
4Dept. of Med., Div. of Hem., Karolinska Institutet, Stockholm, Sweden
5The Finsen Laboratory, Rigshospitalet, Denmark

Development of Acute Megakaryoblastic Leukemia in Down Syndrome Is Associated with Sequential Epigenetic Changes That Target the Down Syndrome Critical Region on Chromosome 21

Maria E Figueroa, MD1*, Sebastien Malinge, PhD2*, Timothy M Chlon3*, Yushan Li4*, Elisabeth Paietta, PhD5, Hugo F. Fernandez, MD6, Martin S. Tallman, MD7, Mitchell J Weiss, MD8, Stella T Chou, MD9, Ari Melnick, MD10* and John Crispino, PhD11

1Pathology, University of Michigan Medical School, Ann Arbor, MI
2Hematology/oncology, Northwestern University, Chicago, IL
3Northwestern University, Chicago, IL
4Department of Medicine, Hematology Oncology Division, Weill Cornell Medical College, New York, NY
5Montefiore Medical Center, Bronx, NY
6Blood and Bone Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Instittute, Tampa, FL
7Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
8Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA
9Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA
10Department of Medicine, Weill Cornell Medical College, New York, NY
11Division of Hematology/Oncology, Northwestern University, Chicago, IL

Sox4 and CREB Cooperate in Myeloid Transformation

Salemiz Sandoval, Ph.D.1*, Michelle Cho1*, Christina Kraus1*, Er-Chieh Cho, Ph.D.1*, Linda Wolff, PhD2 and Kathleen M. Sakamoto, MD, PhD1

1Pediatrics, David Geffen School of Medicine, UCLA, Los Angeles, CA
2NCI, NIH, Bethesda, MD

Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in T-Cell Acute Lymphoblastic Leukemia

Takaomi Sanda, M.D., Ph.D.1, Lee N Lawton, PhD2*, M Inmaculada Barrasa, Ph.D.2*, Zi Peng Fan2*, Yebin Ahn1*, Richard Young, PhD2* and A. Thomas Look, M.D.1

1Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
2Whitehead Institute for Biomedical Research, Cambridge, MA

Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures

Jason H. Mendler, MD, PhD1, Kati Maharry, MAS1*, Michael D. Radmacher, PhD1*, Krzysztof Mrózek, MD, PhD1, Jessica Kohlschmidt, PhD1*, Deedra Nicolet, MS1*, Heiko Becker, MD1, Klaus H. Metzeler, MD1, Sebastian Schwind, MD1*, Susan P. Whitman, PhD1*, William Blum, MD1, Bayard L. Powell, MD2, Jonathan E. Kolitz, MD3, Thomas H. Carter, MD, PhD4*, Meir Wetzler, MD5, Joseph O. Moore, MD6, Andrew J. Carroll, PhD7, Maria R. Baer, MD8, Richard A. Larson, MD9,10, Michael A Caligiuri, MD1, Guido Marcucci, MD11 and Clara D. Bloomfield, MD1

1The Ohio State University Comprehensive Cancer Center, Columbus, OH
2Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC
3Department of Medicine, North Shore-Long Island Jewish Health System, Lake Success, NY
4University of Iowa, Iowa City, IA
5Roswell Park Cancer Institute, Buffalo, NY
6Medicine, Duke University Medical Center, Durham, NC
7Department of Genetics, University of Alabama at Birmingham, Birmingham, AL
8Greenebaum Cancer Center, University of Maryland, Baltimore, MD
9University of Chicago, Chicago, IL
10Hematology/Oncology and Comprehensive Cancer Center, University of Chicago, Chicago, IL
11Division of Hematology, The Ohio State University, Columbus, OH

Epigenetic Modulation Leads to Re-Expression of Relapse Specific Silenced Genes and Induces Chemosensitivity in Childhood Acute Lymphoblastic Leukemia (ALL)

Teena Bhatla, MD1*, Debra J. Morrison, PhD1*, Jinhua Wang, PhD2*, Elizabeth A. Raetz, MD3*, Michael Burke, MD4, Patrick Brown, MD5 and William L. Carroll, MD6

1Pediatrics, NYU Langone medical center, New York, NY
2Pedatrics, New York University Langone Medical Center, New York, NY
3New York University Langone Medical Center, New York, NY
4Pediatric Hematology-Oncology-Blood and Marrow Transplantation, University of Minnesota Children's Hospital-Fairview, Minneapolis, MN
5Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
6New York University Cancer Institute, New York, NY

Altered Regulation of Imprinted Non-Coding RNA Genes in Acute Myeloid Leukemia

Ming-Yu Yang, PhD1,2*, Jan-Gowth Chang, MD2,3*, Pai-Mei Lin, PhD4*, Jui-Feng Hsu, MD5*, Cheng-Han Wu, MD2*, Wen-Chi Yang, MD2*, Yi-Chang Liu, MD3,5*, Hui-Hua Hsiao, MD3,5* and Sheng-Fung Lin, MD2,3

1Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University-Kaohsiung Division, Kaohsiung County, Taiwan
2Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
3Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
4Department of Nursing, I-Shou University, Kaohsiung County
5Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan

5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells

Viviane Ghanim, M.D.1*, Harald Herrmann, MD2*, Emir Hadzijusufovic, DVM1,3*, Barbara Peter, D.V.M.2*, Katharina Blatt, M.Sc.1*, Karina Schuch4*, Sabine Cerny-Reiterer, D.V.M.1*, Irina Mirkina, PhD2*, Gerwin Heller, PhD5*, Sabine Zöchbauer-Müller, MD5*, Heidrun Karlic, PhD2*, Winfried F Pickl, MD4* and Peter Valent, M.D.1,2

1Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
2Ludwig Boltzmann Cluster Oncology, Vienna, Austria
3Department for Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine of Vienna, Vienna, Austria
4Institute of Immunology, Medical University of Vienna, Vienna, Austria
5Department of Internal Medicine I, Division of Clinical Oncology, Medical University of Vienna, Vienna, Austria

MicroRNA Profiling Reveals Aberrant MicroRNA Expression in Adult ETP-ALL and Functional Studies Demonstrate a Role of Mir-222 in Acute Leukemia

Ebru Coskun, MS1*, Martin Neumann1*, Cornelia Schlee, MS1*, Nicola Goekbuget, MD2, Dieter Hoelzer, MD2*, Eckhard Thiel1 and Claudia D Baldus, MD1*

1Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany
2Medical Department II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Frankfurt, Germany

Haploinsufficiency of Dnmt1 Impairs Leukemia Stem Cell Function Through Derepression of Bivalent Chromatin Domains

Jennifer J. Trowbridge, PhD1, Amit U. Sinha2*, Scott A. Armstrong, MD, PhD2 and Stuart H. Orkin, MD1

1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital Boston, Harvard Stem Cell Institute, Howard Hughes Medical Institute, Boston, MA
2Pediatric Hematology Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Boston, MA

Therapeutic Potential of Targeted HOXA-TALE Knockdown in AML

Glenda Joanne Dickson, PhD1*, Kathleen A O'Hagan, PhD1*, Damian PJ Finnegan, MRCP, FRCPath, PhD2*, Mary Frances McMullin, MD3, Ken I. Mills, PhD, FRCPath1, Terence R.J. Lappin, PhD, FRCPath1 and Alexander Thompson, BSc, MSc, PhD4

1Haematology, Queen's University Belfast, Belfast, United Kingdom
2Department of Haematology, Royal Perth Hospital, Perth, Australia
3Belfast City Hospital Department of Haematology, Queens University of Belfast, Belfast, United Kingdom
4Hem./CCRCB, Queen's Univ. Belfast, Belfast, United Kingdom

MiR-150 Suppresses MLL-AF9 Associated Leukemia Through Simultaneously Targeting Multiple Oncogenes

Beiyan Zhou, PhD

Depart of Physiology and Pharmacology, Texas A&M University, College Station, TX

Repression of Mir-495, a Microrna Associated with Favorable Outcome of Acute Myeloid Leukemia Patients, Is Required for the MLL-Associated Leukemogenesis

Xi Jiang, PhD*, Hao Huang, PhD, Zejuan Li, MD, PhD, Yuanyuan Li*, Ping Chen, MD, Chunjiang He, PhD*, Stephen Arnovitz*, Mary Beth Neilly*, Janet D. Rowley, MD and Jianjun Chen, PhD

Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL

5-Azacytidine and Decitabine Induce Demethylation and Re-Expression of FAS (CD95) and Promote Apoptosis in Neoplastic Cells in Acute Myeloid Leukemia (AML)

Heidrun Karlic, PhD1*, Rene Reitermaier1,2*, Viviane Ghanim, MD3*, Harald Herrmann, MD1,4*, Roman Thaler, M.Sc. PhD5*, Silvia Spitzer5*, Franz Varga, PhD5*, Irina Sadovnik, M.Sc.3*, Katharina Blatt, M.Sc.3*, Felix Keil, MD2, Peter Valent, M.D.1,3 and Michael Pfeilstöcker, MD2

1Ludwig Boltzmann Cluster Oncology, Vienna, Austria
23rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
3Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
4Department of Internal Medicine I, Division of Hematology and Hemostaseology , Medical University of Vienna, Vienna, Austria
5Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK and AUVA Trauma Center Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria

The Role of the Intrinsically Disordered and Multifunctional AF9 C-Terminal Domain in MLL-AF9 Leukemia

John H. Bushweller, PhD1, Benjamin Leach2*, Ming-jin Chang3*, Bhavna Lumba3*, Tomasz Cierpicki, PhD4*, Nancy J. Zeleznik-Le, PhD5 and Charles S. Hemenway, MD, PhD6

1Mol. Physiology & Biological Physics, University of Virginia, Charlottesville, VA
2University of Virginia, Charlottesville, VA
3Loyola University Chicago, Maywood, IL
4Pathology, University of Michigan, Ann Arbor, MI
5Oncology Institute, Department of Medicine, Loyola University Medical Center, Maywood, IL
6Loyola University Medical Center, Maywood, IL

Genomic Heterogeneity in B-Cell Malignancies

Daphne R. Friedman, M.D.1 and Joseph R. Nevins, Ph.D.2*

1Medicine, Duke University Medical Center, Durham, NC
2Institute for Genome Sciences and Policy, Duke University, Durham, NC

Essential Role for PU.1 in MEIS1 Activation and MLL Fusion Leukemia

Jing Zhou1*, Bo Li1,2*, Jun Wu1*, Fuhong He1*, Qiang Li1*, Xiaomei Yan2*, Yue Zhang2*, Lixia Zhang1*, Xinghui Zhao2*, Jin Yan1*, Marcelo Nobrega3*, Daniel G. Tenen, MD4,5, Gang Huang2 and Qian-fei Wang1

1Laboratory of Disease Genomics and Individualized Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
2Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
3Department of Human Genetics, University of Chicago, Chicago, IL
4Cancer Science Institute, National University of Singapore, Singapore, Singapore
5Harvard Stem Cell Institute , Harvard Medical School, Boston, MA

MOZ Is Critical for MOZ/MLL-Fusion-Induced HoxA9/Meis1 Expression and Leukemia Development

Takuo Katsumoto, PhD1* and Issay Kitabayashi, PhD2

1Division of Hematological Malignancy, National Cancer Center, Tokyo, Japan
2Divsion of Hematological Malignancy, National Cancer Center, Tokyo, Japan

Loss of EZH2 and Aberrant DNA Methylation Account for PKC412 Drug Resistance in the FLT3-ITD Positive Acute Myeloid Leukemia (AML) Cell Line MV4-11

Stefanie Göllner, PhD1*, Tino Schenk, PhD2*, Christian Rohde, PhD1*, Arthur Zelent, PhD2, Friedrich Stölzel, MD3, Christian Thiede, MD3, Wolfgang E. Berdel1 and Carsten Müller-Tidow, MD1*

1Department of Medicine A- Hematology, Oncology and Pneumology, University of Muenster, Muenster, Germany
2Molecular Pathology, Institute of Cancer Research, Sutton, United Kingdom
3Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany

FLT3-ITD Signaling Induces Oncogenic Mir-155 by NF-κB and STAT5 Pathways In Acute Myeloid Leukemia Thereby Targeting Transcription Factor PU.1

Dennis Gerloff1*, Daniela Braeuer-Hartmann1*, Christiane Katzerke1*, Jens-Uwe Hartmann1*, Carsten Mueller-Tidow, MD2*, Daniel G. Tenen, MD3, Dietger Niederwieser, MD4 and Gerhard Behre, MD4*

1Department of Hematology, Oncology and Hemostaseology, University Leipzig, Leipzig, Germany
2Department of Medicine (Hematology/Oncology/Pneumology), University of Muenster, Germany
3Harvard Stem Cell Institute , Harvard Medical School, Boston, MA
4Dept. of Hematology and Oncology, University of Leipzig, Leipzig, Germany

Successive Development of T-Cell Acute Lymphoblastic Leukemia, Non-Langerhans-Cell Histiocytose and Histiocytic Sarcoma with a Common Origin: Evidence for Common Oncogenetic Transformation Before Full Lineage Commitment

D. Maroeska W.M. te Loo, MD, PhD1, Esmé Waanders, PhD2*, Patricia JTA Groenen3*, Annet Simons4*, Jacques J.M. van Dongen, PhD5*, Peter M. Hoogerbrugge, MD, PhD6 and Konnie M Hebeda7*

1Pediatric Hemato-Oncology, UMCN St Radboud, Nijmegen, Netherlands
2Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
3Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
4Human Genetics, , Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
5Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
6Department of Pediatric Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
7Department of Pathology, , Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Promoter and Exon 1 Hypermethylation of the Tumor Suppressor Gene PRDM1/Blimp-1 indicates Its Pathogenetic Role in EBV-Positive Burkitt Lymphoma

Kui Nie, PhD1*, Taotao Zhang, MD, PhD1*, Carlos E Bacchi, MD2*, Eduardo Queiroga, MD2*, Dra. Gabriela Gualco, MD2*, Jiong Yan, MD, PhD1*, Yifang Liu, MD1*, Sharon Barouk1*, Attilio Orazi, MD1*, Daniel M Knowles, MD3* and Wayne Tam, MD, PhD1

1Department of Pathology & Laboratory Medicine, Weill Cornell Medical College, New York, NY
2Consultoria em Patologia, Brazil
3Department of Pathology and Laboratory Medicine, Weill-Cornell Medical College, New York, NY

Identification of An Abnormal JAK2 WT CD34+ Cell Population Characterized by High Bcl-Xl Expression Levels Both in JAK2 Positive and Negative PV, ET and PMF Patients

Daniela Cilloni, MD, PhD1, Valentina Rosso2*, Marina Podestà, PhD3*, Enrico Bracco, PhD4*, Federica Benvenuto5*, Sonia Carturan6*, Giovanni Barosi, MD7, Vittorio Rosti, MD8, Giuseppe Saglio, MD1 and Francesco Frassoni, MD9*

1Dept. of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
2Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
3Dipartimento di Ematologia, Ospedale San Martino, Genova, Italy
4Department of Clinical and Biological Sciences, University of Turin, Orbassano,Turin, Italy
5Ospedale S.Martino, Centro Cellule Staminali e Terapia Cellulare, Genova, Italy
6department of clinical and biological sciences, University of Turin, turin, Italy
7Clinical Epidemiology/Center for the Study of Myelofibrosis, IRCCS Policlinico S.Matteo Foundation, Pavia, Italy
8Lab. of Clinical Epidemiology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
9Centro Cellule Staminali e Terapie Cellulari, Ospedale San Martino, Genoa, Italy

Cytokine/Chemokine Expression with Protein Arrays Identifies Three Subsets of T-Cell Lymphomas with Differented Immunological Profiles

Santiago Mercadal Sr.1,2*, Antonio Martinez3*, Lluis Colomo, MD, PhD4*, Elias Campo3* and Armando Lopez-Guillermo, MD5

1Hematology, Institut Catala d'Oncologia, Hospitalet de Llobregat, Spain
2Hematology, Institut Catala d'Oncologia, L'Hospitalet de LLobregat, Barcelona, Spain
3Hematopathology Unit, Hospital Clinic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain
4Department of Pathology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
5Department of Hematology, Hospital Clínic, Barcelona, Spain

Genomewide Detection of Genes Targeted by Aberrant Somatic Hypermutation in Lymphoma

Yanwen Jiang, PhD1, David Soong, Ph.D.1*, Chuanxin Huang, PhD2*, Stefano Monni, Ph.D.3*, Ari Melnick, MD2* and Olivier Elemento, PhD1*

1Institute for Computational Biomedicine and Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY
2Department of Medicine, Weill Cornell Medical College, New York, NY
3Department of Public Health, Weill Cornell Medical College, New York, NY

MMSET Contributes to Multiple Myeloma Oncogenesis Through Induction of Global Epigenetic Changes and Alteration of the DNA Damage Response

Relja Popovic, PhD1*, Eva Martinez-Garcia, PhD1*, Steve M.M Sweet, PhD2*, Yupeng Zheng, PhD2*, Neil L Kelleher, PhD2* and Jonathan D. Licht, MD3

1Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
2Department of Molecular Biosciences, Northwestern University, Evanston, IL
3Northwestern Univ. Feinberg Sch. of Med., Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

Genomewide DNA Methylation Analysis Reveals Specific Signatures in Childhood B-Lymphoblastic Leukemias

Seung-Tae Lee1*, Yuanyuan Xiao2*, Marcus O. Muench3*, Jianqiao Xiao1*, Ivan Smirnov4* and Joseph L. Wiemels, PhD5

1Laboratory for Molecular Epidemiology, Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA
2Division of Biostatistics, Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA
3Blood Systems Research Institute and Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
4Division of Biostatistics, Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco
5UCSF, San Francisco, CA

Genomic and Molecular Properties of Relapsed CNS Lymphoma Using Novel Primary Meningeal Lymphoma Cell Lines and Intracranial Xenografts

Hua-Xin Gao, Ph.D.1*, Shawn Anderson2*, Lingjing Chen, Ph.D.3*, Cigall Kadoch, BA4, Byron C Hann, MD, PhD5*, Clifford Lowell, MD, PhD6*, Colin Collins, Ph.D.7* and James L. Rubenstein, M.D., Ph.D.8

1Medicine, UCSF
2Vancouver Prostate Center
3Medicine, UCSF, San Francisco, CA
4UCSF
5Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
6Univ. of CA, San Francisco, San Francisco, CA
7University of British Columbia
8Hematology/Oncology, University of California, San Francisco, CA

Transcriptome-Wide Analysis of Polyadenylation Sites in Mantle Cell Lymphoma Using Polyadenylation Signal Sequencing

Marc A. Weniger, PhD1*, Delong Liu, Ph.D.1*, Ting Ni, Ph.D.2*, Jun Zhu, Ph.D.2* and Adrian Wiestner, MD, PhD1

1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
2DNA Sequencing and Computational Biology Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD

*signifies non-member of ASH